FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma

Trial

HORIZON

Drug

Pepaxto (melphalan flufenamide) · Peptidase-enhanced nitrogen mustard

Condition

Plasma cell